All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
SOHO 2019 | Which classes of drugs are used for non-antibody based immunotherapies in MM?
Bookmark this article
During SOHO 2019, Houston, US, the Multiple Myeloma Hub were pleased to talk with Dr Nina Shah from University of California, San Francisco, US, about different classes of drugs used as non-antibody based immunotherapies in multiple myeloma.
Dr Shah highlights promising results of CAR T-cells, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates.
Which classes of drugs are used for non-antibody based immunotherapies in MM?
Your opinion matters
27 votes - 5 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox